Publications by authors named "Youli Xia"
Unlabelled: KRAS inhibitors have demonstrated exciting preclinical and clinical responses, although resistance occurs rapidly. Here, we investigate the effects of KRAS-targeting therapies on the tumor microenvironment using a library of KrasG12D, p53-mutant, murine pancreatic ductal adenocarcinoma-derived cell lines (KPCY) to leverage immune-oncology combination strategies for long-term tumor efficacy. Our findings show that SOS1 and MEK inhibitors (SOS1i+MEKi) suppressed tumor growth in syngeneic models and increased intratumoral CD8+ T cells without durable responses.
View Article and Find Full Text PDFArticle Synopsis
- Liquid biopsy, specifically plasma ctDNA analysis, has potential but its effectiveness in capturing detailed tumor characteristics for clinical use is still being explored.
- In a study with 459 metastatic breast cancer patients, machine learning techniques were applied to ctDNA to uncover complex biological features similar to traditional tumor tissue analysis.
- The research identified four DNA subtypes and a specific ctDNA genomic signature linked to poor treatment response and survival outcomes, highlighting the potential for ctDNA to serve as a valuable predictor in cancer treatment.
The AURORA US Metastasis Project was established with the goal to identify molecular features associated with metastasis. We assayed 55 females with metastatic breast cancer (51 primary cancers and 102 metastases) by RNA sequencing, tumor/germline DNA exome and low-pass whole-genome sequencing and global DNA methylation microarrays. Expression subtype changes were observed in ~30% of samples and were coincident with DNA clonality shifts, especially involving HER2.
View Article and Find Full Text PDFPurpose: Endocrine therapy resistance (ETR) remains the greatest challenge in treating patients with hormone receptor-positive breast cancer. We set out to identify molecular mechanisms underlying ETR through in-depth genomic analysis of breast tumors.
Experimental Design: We collected pre-treatment and sequential on-treatment tumor samples from 35 patients with estrogen receptor-positive breast cancer treated with neoadjuvant then adjuvant endocrine therapy; 3 had intrinsic resistance, 19 acquired resistance, and 13 remained sensitive.
Breast cancer is classified into multiple distinct histologic types, and many of the rarer types have limited characterization. Here, we extend The Cancer Genome Atlas Breast Cancer (TCGA-BRCA) dataset with additional histologic type annotations, in a total of 1063 breast cancers. We analyze this extended dataset to define transcriptomic and genomic profiles of six rare special histologic types: cribriform, micropapillary, mucinous, papillary, metaplastic, and invasive carcinoma with medullary pattern.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on using a computational method to understand how changes in DNA copy number relate to tumor characteristics in precision medicine, especially for breast cancers.
- By analyzing gene expression patterns, researchers can predict various tumor traits, such as growth status and estrogen signaling, based solely on DNA features.
- This methodology is applicable to multiple cancer types, with findings suggesting that DNA-based predictors could serve as valuable biomarkers for tailored treatment decisions.
Peritoneal adhesion occurs in a majority of patients following abdominal surgery and can result in significant side effects and complications. Current strategies to minimize adhesions involve the use of nontargeted anatomical barriers that are either inefficient in protecting injured areas or lacking the adequate residence time to prevent adhesions. Herein, the development of a biologically targeted photo-crosslinkable nanopatch (pCNP) is reported that can prevent postsurgical adhesion.
View Article and Find Full Text PDF